Amylyx Pharmaceuticals is a biopharmaceutical company that is developing a small-molecule therapeutic for neurodegenerative diseases. Their lead candidate is a combination therapy using two clinically approved drugs that target mitochondrial stress and ER stress. They have formulated a superior formulation of these two components and are currently conducting preclinical testing for amyotrophic lateral sclerosis and Alzheimer's disease. Amylyx is dedicated to providing innovative solutions for neurodegenerative diseases and has a highly motivated team focused on streamlined clinical development and drug discovery.